Finanzen von Editas Medicine Inc (EDIT)EDITEditas Medicine Inc

Evaluating the bottom line, Editas Medicine, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -167.31%, while the net margin is -153.32%. These profitability ratios, combined with a Return on Equity (ROE) of -118.82%, provide a clear picture of how effectively EDIT converts its operational activities into shareholder value.

In the context of the broader market, EDIT competes directly with industry leaders such as GALT and KYTX. With a market capitalization of $396.24M, it holds a leading position in the sector. When comparing efficiency, EDIT's gross margin of 100.00% stands against GALT's N/A and KYTX's N/A. Such benchmarking helps identify whether Editas Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Editas reported a narrower net loss of $18.23 million in Q2 2026, improving from a loss of $53.23 million in the same quarter last year. R&D revenue grew to $11.89 million, up from $3.58 million a year earlier, indicating effective partnership management and growth in revenue streams.